Answers are grounded in this paper and cite their sources.
Several potential therapeutic targets for antibody drug conjugates (ADCs) have been highlighted in breast cancer, including, among the others, HER2, TROP-2, PTK7, and LIV-1 (Figure 1) (Table 1) [1]...
No takes yet. Share an insight, caveat, or question.
Rizzo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: